Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 307 results found since Jan 2013.
Dramatic Increase in Use of Radial Artery Access for PCI in the U.S.
In the last six years interventional cardiologists have dramatically increased their use of radial access for PCI, according to a retrospective study published in Circulation. Using data from the CathPCI registry on more than 2.8 million procedures between January 2007 and September 2012, Dmitriy Feldman and colleagues found that radial access PCI increased 13-fold, from a negligible 1.2% at the beginning of the study to 16.1% at the end. … Click here to read the full story in Forbes. Infographic from the American Heart Association
Source: CardioBrief - June 10, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized american heart association Cardiology Conventional PCI Percutaneous coronary intervention Source Type: blogs
A CME Program Begs The Question: Promotion Or Education?
In recent years defenders of commercially-supported continuing medical education (CME) have claimed that the industry has cleaned up its act and that CME programs today are largely free of the abuses that were so common not so long ago. Perhaps. But there are still plenty of examples of programs that violate the fundamental principle that medical education should be completely separate from commercial interests. A striking example is a recent email I received from TCTMD, the online arm of the Cardiovascular Research Foundation (CRF), which is basically the equivalent of the Vatican for interventional cardiologists. More…
Source: CardioBrief - June 2, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics CME Columbia University Continuing education Continuing medical education Intravascular ultrasound IVUS Stent Source Type: blogs
Spinning RECORD: Battle Over Rosiglitazone Heats Up Two Weeks Before Crucial FDA Meeting
Battle lines are being drawn two weeks before a highly unusual two-day FDA advisory committee meeting to discuss the contentious diabetes drug rosiglitazone (Avandia, GlaxoSmithKline). This will be the second time an FDA panel has wrestled with the fate of the drug and expectations have been that the discussion will once again be heated. But at least one source of fierce criticism won’t be participating in the panel. Steve Nissen, who originally raised concerns about the drug and who has remained the most consistent critic of the drug, will not participate in the deliberations or present to More…
Source: CardioBrief - May 24, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes American College of Cardiology Avandia FDA food and drug administration GlaxoSmithKline Nissen Rosiglitazone Source Type: blogs
Small Study Suggests Statins May Blunt Benefits Of Exercise
A small study is raising big questions about whether statins may blunt the beneficial effects of exercise. The study has been published online in the Journal of the American College of Cardiology and was the subject of a New York Times blog today. … The authors concluded: “Given the strong independent cardio-protective effects of increasing cardiorespiratory fitness or lowering LDL, the benefits and risks of each should be carefully considered when choosing treatment modalities.” … Click here to read the full story on Forbes.
Source: CardioBrief - May 22, 2013 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes exercise exercise training Low-density lipoprotein metabolic syndrome obesity Simvastatin Source Type: blogs
Athletes With Defibrillators Don’t Need To Quit Sports
Although the American College of Cardiology and the European Society of Cardiology now advise people with ICDs not to participate in vigorous sports, a new study offers strong support for people with ICDs who want to take part in sports. Although a large number of people with ICDs are elderly heart failure patients who are unlikely to want to participate in sports, ICDs are also implanted in young and otherwise healthy people with genetic diseases that leave them at high risk for lethal arrhythmias. Now findings from the ICD Sports Safety Registry, published in Circulation, provide vital new More…
Source: CardioBrief - May 21, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Policy & Ethics Prevention, Epidemiology & Outcomes Arrhythmogenic right ventricular dysplasia athletes Cardiac dysrhythmia Heart disease Hypertrophic cardiomyopathy ICDs Long QT syndrome sports Source Type: blogs
Novel Leadless Pacemaker Makes Debut At HRS 2013
First results in human patients of a novel leadless pacemaker were presented last week at the HRS meeting in Denver by Vivek Reddy. Pacemaker leads are the most common source of complications associated with pacemakers today. The self-contained device is delivered via catheter to the right ventricle, to which it is attached with a fixation mechanism. The device is manufactured by Nanostim, Inc, a small company which is being acquired by St. Jude Medical. … Click here to read the full story on Forbes.
Source: CardioBrief - May 13, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery Heart Rhythm Society leadless pacemaker Nanostim st jude medical Source Type: blogs
Our Limitless Capacity For Self-Deception
I want to share with my readers a recent post and accompanying comment published on CardioExchange. The original post is by Eric Lindley, a cardiology fellow at the University of Utah: Journal X: Not so Subtle Marketing Messages I was the rare resident who thought that conflict of interest issues in medicine were a bit overblown. I did not find (or ignored) the evidence that pharma played a role in prescribing habits very persuasive, at least not when it came to my personal prescribing habits. I was not alone among the house staff, however, in appreciating an More…
Source: CardioBrief - May 12, 2013 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics advertising conflict of interest medical ethics Source Type: blogs
Encouraging 4 Year Results For Watchman Device In AF Patients
Encouraging long-term results from the PROTECT AF trial comparing the Watchman left atrial appendage closure device to warfarin in atrial fibrillation patients were presented yesterday at the Heart Rhythm Society meeting in Denver. Previously, the main results of the trial, published in the Lancet, demonstrated that the Watchman was noninferior to warfarin, but the total number of events in the trial was small. In addition, there were more safety problems, as might be expected, in the early days after implantation. The FDA required the company to perform a confirmatory trial. That trial, PREVAIL, has been the subject ...
Source: CardioBrief - May 10, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery Policy & Ethics atrial fibrillation Boston Scientific food and drug administration Heart Rhythm Society warfarin Watchman Source Type: blogs
Burton Sobel, Towering Cardiologist, Dead At 75
Burton Sobel, a towering scientist and cardiologist, died at home on May 3 at the age of 75. Sobel had been treated in the past for prostate cancer and had suffered a recurrence, but it is not known if this was the immediate cause of his death. Sobel was among the most powerful and influential cardiologists in the 1980s when he played a key early role in the development of fibrinolysis and the first major biotechnology product, TPA. From his perch as the chief of cardiology at Washington University in Saint Louis and as the More…
Source: CardioBrief - May 7, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Allan Jaffe Circulation eugene braunwald Sobel TPA Washington University Source Type: blogs
Metaanalysis Finds Same Day Discharge For Low Risk PCI May Be Feasible
Although elective PCI for most low risk patients is extremely safe, overnight observation is still standard practice in the US, largely due to the lack of evidence demonstrating that same-day discharge is safe. Now a new metaanalysis, published online in the Journal of the American College of Cardiology, provides support for same-day discharge in carefully selected low-risk patients. … Click here to read the full post on Forbes.
Source: CardioBrief - May 6, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
Japanese Research Scandal Expands To A Second Trial And A Novartis Employee
A Japanese research scandal, which has so far centered on actions taken by the once-prominent cardiologist Hiroaki Matsubara, has now expanded. As has been previously reported, several papers authored by Matsubara have been retracted, including, most notably, the main publication of the Kyoto Heart Study in the European Heart Journal. Now, however, questions have been raised about another clinical trial, the Jikei Heart Trial, which was published in the Lancet in 2007. (Matsubara was not involved in this trial.) Novartis, which manufactures valsartan (Diovan), the drug studied in both trials, has announced that it is More…
Source: CardioBrief - May 2, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics European Heart Journal Lancet Matsubara Novartis scientific misconduct valsartan Source Type: blogs
Edwards CEO Sold Stock 2 Weeks Before It Tanked
Earlier this week the stock of Edwards Lifesciences tanked after the company announced weak Sapien sales and lowered its sales guidance for the rest of the year. The stock, which had been trading in the low 80s for the past month, dropped a heartbreaking 22% on Wednesday in response to the news and closed at 65 on Thursday. But Edwards chairman and CEO Michael Mussallem didn’t suffer along with his shareholders. As reported by GuruFocus, Mussallem sold 35,000 shares of his stock on April 10 at 83.37 per share netting him nearly $3 million. Another More…
Source: CardioBrief - April 26, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Edwards Lifesciences Corporation Sapien TAVR Source Type: blogs
Study Suggests Benefit For Beta Blockers During Noncardiac Surgery
The use of perioperative beta-blockade for noncardiac surgery has been declining as a result of the controversial POISE study, which turned up evidence for harm associated with extended-release metoprolol in this setting. Now a large new observational study published in JAMA offers a contrary perspective by suggesting that perioperative beta-blockade may be beneficial in low- to intermediate-risk patients. But without better evidence the debate about this topic is unlikely to be resolved. Martin London and colleagues performed a retrospective analysis of 136,745 patients who underwent noncardiac surgery at VA hospitals, 40...
Source: CardioBrief - April 23, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes beta blockers JAMA Observational study Source Type: blogs
Actelion Executive To Head American College of Cardiology
Shalom “Shal” Jacobovitz will be the new chief executive officer of the American College of Cardiology, the ACC announced today. Jacobovitz is currently the president of the US division of Actelion Pharmaceuticals, best known for its pulmonary hypertension drugs. Click here to read the complete story on Forbes.
Source: CardioBrief - April 22, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized Actelion American College of Cardiology Jacobovitz Source Type: blogs
Blood Sample Mismatch Leads ‘Anguished’ Authors To Retract Three Lipitor Papers
Three substudies of the influential TNT (Treating to New Targets) trial have been retracted after the sponsor of the trial, Pfizer, discovered that blood samples from the study had been matched to the wrong participants. The main results of TNT, published in 2005 in the New England Journal of Medicine, had a major impact on clinical practice and statin prescription patterns. The trial supported the increasingly aggressive use of statins and helped to solidify the enormous commercial success of atorvastatin (Lipitor, Pfizer). The 3 newly-retracted substudies do not appear to affect the main finding of TNT. Two paper...
Source: CardioBrief - April 16, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized American Heart Journal atorvastatin journal of the american college of cardiology Lipitor Pfizer Source Type: blogs
